The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…marijuana and the recent resurgence of interest in its medicinal properties have been the subject of excellent reviews (Mechoulam, 1986; Iversen, 2000; Di Marzo et al., 2004; Howlett et al., 2004; Pertwee, 2005a; Piomelli, 2005; Di Marzo and Petrocellis, 2006; Mackie, 2006; Pagotto et al., 2006).”
BackgroundVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Self-citationEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Ikoma, A., Steinhoff, M., Ständer, S., Yosipovitch, G., & Schmelz, M. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1950 · Cited by 949
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
“An interesting aspect of endocannabinoid activity is the rapid induction of their synthesis, receptor activation, and degradation (3, 102).”
BackgroundTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
“However, new generations of endocannabinoid-manipulating drugs designed almost entirely in silico or screened out of libraries of compounds have been developed and are either being tested in clinical trials or already on the marke”
BackgroundSelf-citationDrug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Endocannabinoid control of food intake and energy balance
Di Marzo, V., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 743
Self-citationCannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., Kelsch, W., Jacob, W., Marsch, R., Ekker, M., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.006 · Cited by 706
“…2001; van der Stelt et al., 2002; Lutz, 2004) and the proposed therapeutic exploitation of this system for the treatment of several diseases (Di Marzo et al., 2004; Mackie, 2006), it is of central importance to determine in detail which neuronal subtypes are controlled by the endogenous…”
Paracetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
“6 ìg h mL in fasted and fed healthy volunteers, respectively (207); food reduced the maximum concentration of oral paracetamol by 49% (207) [when paracetamol is coadministered with food, the absorption rate of the drug is decreased; for rapid relief of pain, paracetamol should not be taken with food or after a meal, e…”
BackgroundMatias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 656
“This is not surprising in consideration of the fact that these compounds are biosynthesized and metabolized via different pathways (1, 2).”
BackgroundInfluentialSelf-citationAnti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 593
“The endocannabinoid system has been identified as playing a significant role in the control of appetite as well as glucose metabolism [17].”
BackgroundEndocannabinoids Mediate Neuron-Astrocyte Communication
Navarrete, M., & Araque, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.029 · Cited by 581
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
“…in the regulation of neurotransmission) and antagonists of these receptors has stimulated interest in the medical uses of cannabis (Baker et al., 2003; Iversen, 2003; Di Marzo et al., 2004). c i p s t m e I a n s 2 ( lant, antiemetic, muscle relaxant and anticonvulsant properties f cannabis.”
BackgroundDysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Blüher, M., Engeli, S., Klöting, N., Berndt, J., Fasshauer, M., Bátkai, S., Pacher, P., Schön, M. R., Jordan, J., & Stumvoll, M. (2006) · Diabetes · doi:10.2337/db06-0812 · Cited by 530
“At least two G-protein–coupled cannabinoid receptors (CB1 and CB2) have been identified (3,4).”
BackgroundCB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
“Studies have shown that endogenous lipidic cannabinoid ligands and their receptors, CB1 and CB2 (refs”
BackgroundCANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
“Pharmacological inhibitors for endocannabinoid transport have nonetheless been developed (AM404, VDM11, and others) [7,74,87,88].”
BackgroundPhillis, J. W., Horrocks, L. A., & Farooqui, A. A. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.02.002 · Cited by 459
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 443
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
“Contrary to most neurotransmitters, anandamide and 2-AG are formed postsynaptically mostly when and where needed [10,41,57].”
BackgroundSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
“They are not stored and are rapidly degraded after exerting a transient and localized effect[38].”
BackgroundEndocannabinoid signalling and the deteriorating brain
Di Marzo, V., Stella, N., & Zimmer, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3876 · Cited by 382
Self-citationDi Marzo, V. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 368
“…development, transmission and inflammation, cardiovascular, respiratory and reproductive functions, hormone release and action, bone formation and energy metabolism, as well as cellular functions, such as cell architecture, proliferation, motility, adhesion and apoptosis [84] [85] [86] [87].”
BackgroundSelf-citationEndocannabinoids and the control of energy balance
Matias, I., & Di Marzo, V. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.11.006 · Cited by 365
Self-citationMarsch, R., Foeller, E., Rammes, G., Bunck, M., Kössl, M., Holsboer, F., Zieglgänsberger, W., Landgraf, R., Lutz, B., & Wotjak, C. T. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3303-06.2007 · Cited by 359
“Conversely, potentiation of endocannabinoid signaling, for instance by blocking anandamide reuptake and degradation (Di Marzo et al., 2004), may at the same time decrease fear and anxiety in a CB1-dependent manner (for review, see Viveros et al., 2005; Wotjak, 2005) but promote fear and anxiety in…”
BackgroundReview article: The impact of obesity on reproduction in women with polycystic ovary syndrome
Pasquali, R., Gambineri, A., & Pagotto, U. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00990.x · Cited by 359
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Rosenbaum, C. D., Carreiro, S. P., & Babu, K. M. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0202-2 · Cited by 355
The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells
Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.005 · Cited by 352
“One of the most exciting areas of current research in the cannabinoid field is the study of the potential application of cannabinoids as therapeutic agents (Di Marzo et al., 2004; Piomelli, 2003).”
BackgroundObserving others: multiple action representation in the frontal lobe.
Nelissen, K., Luppino, G., Vanduffel, W., Rizzolatti, G., & Orban, G. A. (2005) · Science · doi:10.1126/science.1115593 · Cited by 352
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
Gamble, L.-J., Boesch, J. M., Frye, C. W., Schwark, W. S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E. S., & Wakshlag, J. J. (2018) · Frontiers in Veterinary Science · doi:10.3389/fvets.2018.00165 · Cited by 343
“In lower vertebrates, CBD is also reported to have immunomodulatory (14), anti-hyperalgesic (15, 16), antinociceptive (17, 18), and anti-inflammatory actions (5, 19), making it an attractive therapeutic option in dogs with OA.”
BackgroundPromising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., & Rogers, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902743106 · Cited by 330
“Mouse calvarial osteoblasts were isolated from the calvarial bones of 2-day-old C57BL/6 mice by sequential collagenase digestion and grown to confluence as previously described (1).”
BackgroundMethodGlycerolipid Metabolism and Signaling in Health and Disease
Prentki, M., & Madiraju, S. R. M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0007 · Cited by 326
“Thus, it is important to realize that 2-AG might be generated in ample quantities both from plasma membrane and LD/cytosolic-associated DAG and may be able to participate in the activation of CB1/CB2 receptors after its transport out of the cell via a specific EC transporter (281).”
BackgroundBodor, Á. L., Katona, I., Nyíri, G., Mackie, K., Ledent, C., Hájos, N., & Freund, T. F. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0442-05.2005 · Cited by 325
“Recent progress in studies of the molecular composition of the endocannabinoid system uncovered a considerable diversity in signaling molecules, receptors, and their interactions (Freund et al., 2003; Di Marzo et al., 2004).”
BackgroundCannabis, the mind and society: the hash realities
Murray, R. M., Morrison, P. D., Henquet, C., & Forti, M. D. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2253 · Cited by 322
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
“Cannabimimetic drugs such as small-molecule cannabinoid receptor agonists and antagonists may be designed to target the ECS and its enzymes and either enhance the bioactivity or activation of endocannabinoids or inhibit their inactivation [3,10].”
BackgroundNon-alcoholic fatty liver disease pathogenesis: The present and the future
Petta, S., Muratore, C., & Craxì, A. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.01.004 · Cited by 285
“Anumber of clinical andexpermental studies have established that obesity is associated with n increased CB1-dependent cannabinoid tone [167–169].”
BackgroundA narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 282
“CBD may also relieve pain by regulating the serotonin 5-HT1A receptor(24) and TRPV1.(128) The therapeutic analgesic potential of a sublingual CBD spray for uncontrolled neuropathic pain was investigated previously in 34 patients (Table 2).”
BackgroundThe endocannabinoid system in obesity and type 2 diabetes
Di Marzo, V. (2008) · Diabetologia · doi:10.1007/s00125-008-1048-2 · Cited by 281
“ECs are produced following an elevation of intracellular Ca levels, and are inactivated when paracrine or autocrine cannabinoid receptor activation is to be terminated [8, 9].”
BackgroundSelf-citationHepatic microcirculation and mechanisms of portal hypertension
Gracia-Sancho, J., Marrone, G., & Fernández-Iglesias, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 274
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018) · Molecules · doi:10.3390/molecules23102478 · Cited by 272
“Production and release of endocannabinoids are mediated, during inflammatory-joint disease, by the generation of pro inflammatory cytokines (interferon [IFN]-c, interleukin (IL-12, IL-15, IL-17, IL-18), chemokines, chemical mediators, such as nitric oxide synthetase (NOS)-2, cyclooxygenase-2 (COX-2), matrix metallopro…”
BackgroundInfluentialMonteleone, P., Matias, I., Martiadis, V., De Petrocellis, L., Maj, M., & Di Marzo, V. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300695 · Cited by 271
“The endocannabinoid system (Di Marzo et al, 2004), consisting of two cannabinoid receptors (CB1 and CB2) and the endogenous ligands anandamide (arachidonoylethanolamide (AEA)) and 2- arachidonoylglycerol (2-AG), has been shown to control feeding in both animals and humans (Cota et al, 2003).”
BackgroundSelf-citationWright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
“This consists of the natural ligands anandamide and 2-arachidonoyl glycerol (2-AG) and other receptors (Di Marzo et al., 2004), and the biosynthetic and degradative enzymes necessary for the formation and inactivation of the endocannabinoids (Piomelli, 2003; Di Marzo et al., 2004).”
BackgroundThe importance of the gut microbiota after bariatric surgery
Aron-Wisnewsky, J., Doré, J., & Clement, K. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.161 · Cited by 261
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 257
An introduction to the endocannabinoid system: from the early to the latest concepts
De Petrocellis, L., & Di Marzo, V. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.013 · Cited by 251
Self-citationCannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injury
Batkai, S., Osei‐Hyiaman, D., Pan, H., El‐Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey‐White, J., Jafri, A., Haskó, G., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7451com · Cited by 246
Unconventional endocannabinoid signaling governs sperm activation via the sex hormone progesterone
Miller, M. R., Mannowetz, N., Iavarone, A. T., Safavi, R., Gracheva, E. O., Smith, J. F., Hill, R. Z., Bautista, D. M., Kirichok, Y., & Lishko, P. V. (2016) · Science · doi:10.1126/science.aad6887 · Cited by 245
Potential Analgesic Mechanisms of Acetaminophen
Smith, H. (2009) · Pain Physician · doi:10.36076/ppj.2009/12/269 · Cited by 245
The endocannabinoid system in brain reward processes
Solinas, M., Goldberg, S. R., & Piomelli, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.130 · Cited by 244
“In contrast, it has been clearly demonstrated that their metabolic degradation diverges (Freund et al., 2003; Piomelli, 2003; Di Marzo et al., 2004; Fride, 2005).”
BackgroundInfluentialKöfalvi, A., Rodrigues, R. J., Ledent, C., Mackie, K., Vizi, E. S., Cunha, R. A., & Sperlágh, B. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4232-04.2005 · Cited by 242
Genetic Dissection of Behavioural and Autonomic Effects of Δ9-Tetrahydrocannabinol in Mice
Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C. T., Lutz, B., & Marsicano, G. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050269 · Cited by 238
“specific endogenous lipid signalling molecules, the endocannabinoids [13–15].”
Clinicians’ Guide to Cannabidiol and Hemp Oils
VanDolah, H. J., Bauer, B. A., & Mauck, K. F. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.003 · Cited by 236
Jekyll and Hyde: Two Faces of Cannabinoid Signaling in Male and Female Fertility
Wang, H., Dey, S. K., & Maccarrone, M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0006 · Cited by 232
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis
Tomko, A. M., Whynot, E. G., Ellis, L. D., & Dupré, D. J. (2020) · Cancers · doi:10.3390/cancers12071985 · Cited by 230
“During the development of Western Medicine, a progressive understanding of cannabis properties led to wider medical and recreational consumption in the 20th century until the use of this plant became marginalized and criminalized, largely due to misinformation, which greatly impacted progress regarding the understandi…”
BackgroundCannabinoid activation of PPARα; a novel neuroprotective mechanism
Sun, Y., Alexander, S. P. H., Garle, M. J., Gibson, C. L., Hewitt, K., Murphy, S. P., Kendall, D. A., & Bennett, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707478 · Cited by 229
“…mediated by CB1 and CB2 receptors, two 7-transmembrane G protein-coupled receptors that have been cloned and well characterized (Howlett, 2002; Di Marzo et al., 2004; Mackie, 2006), although several studies have produced evidence supporting the existence of other non-CB1/non-CB2 G…”
BackgroundSolinas, M., Justinova, Z., Goldberg, S. R., & Tanda, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03880.x · Cited by 228
“It is then quickly eliminated by a twostep process consisting of either re-uptake or diffusion into neurons where it undergoes catabolic cleavage, primarily by fatty acid amide hydrolase (FAAH) (Freund et al. 2003; Piomelli 2003; De Petrocellis et al. 2004; Di Marzo et al. 2004).”
BackgroundMethodInfluentialvan der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., Filippis, D. D., Micale, V., Steardo, L., Drago, F., Iuvone, T., et al. (2006) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-006-6037-3 · Cited by 224
Self-citationEndocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia
Mallet, C., Daulhac, L., Bonnefont, J., Ledent, C., Etienne, M., Chapuy, E., Libert, F., & Eschalier, A. (2008) · Pain · doi:10.1016/j.pain.2008.03.030 · Cited by 223
“The discovery of an involvement of endocannabinoids on pain modulation opens new mechanistic perspectives [12,44].”
BackgroundD'Argenio, G., Valenti, M., Scaglione, G., Cosenza, V., Sorrentini, I., & Di Marzo, V. (2006) · The FASEB Journal · doi:10.1096/fj.05-4943fje · Cited by 222
“Obvious examples of these compounds are inhibitors of anandamide inactivation through cellular re-uptake or enzymatic hydrolysis (23).”
Self-citationTargeting CB2 receptors and the endocannabinoid system for the treatment of pain
Anand, P., Whiteside, G., Fowler, C. J., & Hohmann, A. G. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.003 · Cited by 218
“Similarly, while the CB 2 receptor was originally considered to be expressed primarily in lymphoid tissues in the periphery (Munro et al. 1993, Di Marzo et al. 2004), recent evidence has pointed to a neuronal localization in some regions of the rodent brain (Onaivi et al. 2006), and CB 2…”
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
“…pharmaco- logical modulation of the endocannabinoid system repre- sents a promising strategy in various cardiovascular, inflammatory, metabolic, gastrointestinal and liver disorders (reviewed in Di Marzo et al., 2004; Pacher et al., 2005a, 2006a; Pertwee, 2005b; Mackie, 2006; Mallat et al., 2007).”
BackgroundCannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes
Kamprath, K., Marsicano, G., Tang, J., Monory, K., Bisogno, T., Marzo, V. D., Lutz, B., & Wotjak, C. T. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0153-06.2006 · Cited by 217
“Among them, the cannabinoid CB1 receptor (CB1) (for review, see Di Marzo et al., 2004) plays a special role, because its implication in extinction seems to be restricted to aversive test conditions: whereas genetic ablation or pharmacological blockade of CB1 impairs the extinction of fear memories…”
BackgroundSelf-citationShoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P., & Prather, P. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04346.x · Cited by 207
“Therapeutic agents which modulate the cannabinoid system are effective in treating a wide variety of disorders characterized by inflammation (Di Marzo et al. 2004; Klein 2005).”
BackgroundCannabis use in young people: The risk for schizophrenia
Casadio, P., Fernandes, C., Murray, R. M., & Di Forti, M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.007 · Cited by 206
Cardiovascular Disease Under the Influence of Excess Visceral Fat
Després, J.-P. (2007) · Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e318057d4c9 · Cited by 198
Addy, C., Wright, H., Van Laere, K., Gantz, I., Erondu, N., Musser, B. J., Lu, K., Yuan, J., Sanabria-Bohórquez, S. M., Stoch, A., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.012 · Cited by 198
“The appetitive effects of Cannabis sativa (marijuana) have been known for millennia from its medicinal and recreational use 68 Cell Metabolism 7, 68–78, January 2008 ª2008 Elsevier Inc. (Nicoll and Alger, 2004; Di Marzo et al., 2004).”
BackgroundTherapeutic potential of monoacylglycerol lipase inhibitors
Mulvihill, M. M., & Nomura, D. K. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.10.025 · Cited by 196
“…article as: Mulvihill MM, Nomura DK, Therapeutic potential of monoacylglycerol lipase inhibitors, Life Sci (2012), http:// dx.doi.org/10.1016/j.lfs. 2012.10.025 U N C O R R E C T E D P R O O F 76 impairments that have made its use controversial (Di Marzo et al., 2004; 77 Ligresti et al., 2009).”
BackgroundInfluentialCyclooxygenase-2 in synaptic signaling
Yang, H., & Chen, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480144 · Cited by 195
Cannabinoids and Pain: Sites and Mechanisms of Action
Starowicz, K., & Finn, D. P. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.05.003 · Cited by 193
Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C
Hézode, C., Zafrani, E. S., Roudot–Thoraval, F., Costentin, C., Hessami, A., Bouvier–Alias, M., Medkour, F., Pawlostky, J., Lotersztajn, S., & Mallat, A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.039 · Cited by 190
Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A., & Mukhtar, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603495200 · Cited by 186
Baths Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines
Baumann, M. H., Solis, E., Watterson, L. R., Marusich, J. A., Fantegrossi, W. E., & Wiley, J. L. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3223-14.2014 · Cited by 186
“…system contributes to a number of physiological and pathological processes, including appetite, pain, mental illness, reward, and neurodegenerative diseases (Berry and Mechoulam, 2002; Mechoulam et al., 2002; Walker and Huang, 2002; van der Stelt and Di Marzo, 2003; Di Marzo et al., 2004).”
BackgroundThe endocannabinoid signaling system in cancer
Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C., & Bifulco, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.003 · Cited by 182
Self-citationThe endocannabinoid system in targeting inflammatory neurodegenerative diseases
Centonze, D., Finazzi-Agrò, A., Bernardi, G., & Maccarrone, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.004 · Cited by 182
Greenhough, A., Patsos, H. A., Williams, A. C., & Paraskeva, C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22917 · Cited by 182
“The plant-derived cannabinoid THC is of particular interest for cancer therapy; THC has been shown to promote regression of some tumour types in vivo,(12,13) and is approved for use in the clinic by the US FDA as an antiemetic and appetite stimulant.(49) Furthermore, as part of a small clinical trial, THC has been adm…”
BackgroundBiology of endocannabinoid synthesis system
Wang, J., & Ueda, N. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2008.12.002 · Cited by 180
The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation
Bow, E. W., & Rimoldi, J. M. (2016) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s32171 · Cited by 180
Fitzcharles, M., Baerwald, C., Ablin, J. N., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0084-3 · Cited by 178
“It is hypothesized that cannabinoids function to reduce sensitization of nociceptive sensory pathways and induce alterations in cognitive and autonomic processing in chronic pain states [5, 14].”
BackgroundMoreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177
Miller, L. K., & Devi, L. A. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003491 · Cited by 177
The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids
Marzo, V. D., Bisogno, T., & PETROCELLIS, L. D. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-26573-2_5 · Cited by 177
Self-citationUnderstanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants
Borges, R. S., Batista, J., Viana, R. B., Gonçalves, A. C. B., Orestes, E., de Andrade, M. A., Honório, K. M., & da Silva, A. B. F. (2013) · Molecules · doi:10.3390/molecules181012663 · Cited by 176
“The discovery of endocannabinoids as pain modulators has opened new mechanistic perspectives [1].”
BackgroundThe Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications
Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.11.003 · Cited by 176
“The modulation of the ECS has therapeutic potential in a wide range of disparate diseases and pathologic conditions that affect humans, including neurodegenerative, kidney, and gastrointestinal diseases, pain, cancer, bone and cardiovascular disorders, obesity and metabolic syndrome, and inflammation, just to mention…”
BackgroundInfluentialKeynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists
Lange, J. H. M., & Kruse, C. G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03427-6 · Cited by 176
Horswill, J. G., Bali, U., Shaaban, S., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & Wong Kai In, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707347 · Cited by 175
“British Journal of Pharmacology (2007) 152, 805–814 & 2007 Nature Publishing Group All rights reserved 0007–1188/07 $30.00 www.brjpharmacol.org obesity, nicotine and alcohol dependence, pain, multiple sclerosis, cancer, diarrhoea and cardiovascular diseases (Di Marzo et al., 2004).”
BackgroundInfluentialHejazi, N. S., Zhou, C., Öz, M., Sun, H., Ye, J. H., & Zhang, L. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.019174 · Cited by 175
Review article: endocannabinoids and their receptors in the enteric nervous system
DUNCAN, M., DAVISON, J. S., & SHARKEY, K. A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02648.x · Cited by 155
Cannabinoids and cancer: pros and cons of an antitumour strategy
Bifulco, M., Laezza, C., Pisanti, S., & Gazzerro, P. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706632 · Cited by 173
“CB2 receptors were found in microglia cells (Kearn & Hillard, 1997; Walter et al., 2003; Nunez et al., 2004), in glioma and in skin tumour cells (Casanova et al., 2001; Di Marzo et al., 2004).”
BackgroundSelf-citationThe N‐Acylethanolamine‐Hydrolyzing Acid Amidase (NAAA)
Tsuboi, K., Takezaki, N., & Ueda, N. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790159 · Cited by 172
Cannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells
Klein, T. W., & Cabral, G. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-005-9007-x · Cited by 172
“These compounds are arachidonic acid derivatives arising from the membrane fatty acid matrix of various cells including neurons and immune cells (Sugiura et al. 2002; Di Marzo et al. 2004).”
BackgroundMatias, I., Bisogno, T., & Marzo, V. D. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803271 · Cited by 172
Self-citationFatty acid amide hydrolase deficiency limits early pregnancy events
Wang, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28621 · Cited by 156
“org Volume 116 Number 8 August 2006 2129 Increasing evidence suggests that anandamide synthesis via NAPE-PLD and its release from cells occur only when and where it is needed in vivo (41).”
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.